56
Participants
Start Date
October 31, 2012
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m\^2/dose in combination wit Cyclosporine A or 2.0 mg/m\^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
Novartis Investigative Site, Budapest
Novartis Investigative Site, Budapest
Novartis Investigative Site, Brussels
Novartis Investigative Site, Parkville
Novartis Investigative Site, Torino
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Bergamo
Novartis Investigative Site, Madrid
Novartis Investigative Site, Charleston
Novartis Investigative Site, Hanover
Novartis Investigative Site, Padua
Novartis Investigative Site, Essen
Novartis Investigative Site, Bonn
Novartis Investigative Site, Madison
Novartis Investigative Site, Chicago
Novartis Investigative Site, St Louis
Novartis Investigative Site, Bron
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Salt Lake City
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, Regensburg
Novartis Investigative Site, New York
Novartis Investigative Site, New Haven
Novartis Investigative Site, Houston
Novartis Investigative Site, Edmonton
Novartis Investigative Site, København Ø
Novartis Investigative Site, Roma
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Stockholm
Novartis Investigative Site, West Midlands
Novartis Investigative Site, Leeds
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY